Rising Prevalence of Autoimmune Disorders Drives Growth in the Tysabri Is Contributing To Changes In The Gastric Cancer

Fonte: healthcareresearchreports.com | Data: 30/04/2026 10:02:36

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Gastric Cancer Drugs Market Progress Between 2026 And 2030?

The gastric cancer drugs market has experienced substantial expansion in recent years. Its value is projected to increase from $4.9 billion in 2025 to $5.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. This historical growth can be attributed to several factors, including the rising prevalence of gastric cancer, limited awareness regarding early detection, a reliance on conventional chemotherapy, the increasing adoption of hospital-based treatment, and the high cost of branded drugs.

The gastric cancer drugs market is projected to experience substantial expansion over the coming years, reaching $8.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast period is driven by progress in targeted therapies, increased embrace of immunotherapy, wider application of precision medicine, the creation of new oral and injectable drug forms, and a rise in government and private funding for cancer research. Key developments expected during this period involve tailored gastric cancer treatments, the evolution of targeted drug delivery systems, a greater reliance on combination therapies, the expansion of outpatient cancer care facilities, and improvements in supportive care and symptom management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Leading Drivers Are Supporting The Gastric Cancer Drugs Market Expansion?

The future expansion of the gastric cancer drug market is anticipated to be fueled by the rising global aging population. This demographic trend describes a scenario where a substantial portion of a country’s or area’s inhabitants are elderly, generally those 65 years old and above. It arises from a combination of sustained improvements in life expectancy and declining birth rates, leading to a greater share of older individuals within the total population. Given that older patients often exhibit reduced tolerance for conventional cancer therapies like surgery or chemotherapy, there is an increased demand for customized treatment approaches, specifically drugs, designed to meet their particular needs and sensitivities. For example, data from July 2024, provided by the UK Parliament’s House of Commons Library, indicated that in 2022, the UK had 12.7 million residents aged 65 or older, making up 19% of its total population. This figure is forecast to grow to 22.1 million by 2072, representing 27% of the population. Consequently, the gastric cancer drug market is expected to expand in the future, propelled by the increasing number of elderly individuals.

Which Segment Classifications Are Used In The Gastric Cancer Drugs Market Segment Analysis?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

What Trends Are Shaping The Future Of The Gastric Cancer Drugs Market?

Companies active in the gastric cancer drugs market are concentrating on developing innovative products, such as CLDN18.2-targeted treatments, to enhance therapeutic effectiveness and provide more personalized patient options. A CLDN18.2-targeted treatment involves therapies designed to target claudin 18.2 (CLDN18.2), a protein primarily expressed in certain epithelial tissues, including the gastric epithelium. For example, in October 2024, Astellas Pharma Inc., a Japan-based company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) represents the inaugural and sole CLDN18.2-targeted treatment utilized for advanced gastric and gastroesophageal junction cancer in patients whose tumors are CLDN18.2 positive. This treatment is administered in conjunction with fluoropyrimidine- and platinum-based chemotherapy regimens. It is indicated for adults with locally advanced unresectable negative gastric or gastroesophageal junction cancer adenocarcinoma.

Which Firms Are Contributing To The Gastric Cancer Drugs Market Ecosystem?

Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS

Get The Full Gastric Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Where Is The Gastric Cancer Drugs Market Most Concentrated Geographically?

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastric Cancer Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795